Clinicians need to take a detailed occupational history when evaluating patients with nontransplant bronchiolitis obliterans as the best treatment is prevention from further exposure, and it is ...

The company has two phase 3 development programs underway for the treatment of bronchiolitis obliterans syndrome (BOS) and non-cystic fibrosis bronchiectasis (NCFB). Rare and severe respiratory ...

Her research focuses on bronchiolitis obliterans syndrome (BOS), which is a complication of chronic ... which may lead to earlier treatment. She is also involved in multicenter trials testing new ...

Itacitinib adipate is under clinical development by Incyte and currently in Phase II for Myelodysplastic Syndrome.

Ruxolitinib phosphate is under clinical development by Incyte and currently in Phase III for Coronavirus Disease 2019 (COVID-19) Associated Cytokine Release Syndrome.

There are several causes and clinical settings associated with the CB obliterans lesion ( Box 1). Idiopathic obliterative bronchiolitis ... respiratory distress syndrome. If recovery occurs ...